Background {#Sec1}
==========

Endometrial carcinoma (EC) is one of the most common types of malignancies in the female reproductive system, accounting for 20% to 30% of the total number of malignant tumors in female genital tract. In some developed countries, the incidence of EC is higher than that of cervical cancer, which ranks first among gynecological tumors \[[@CR1]\]. In recent years, the incidence of EC in China has increased year by year and ranked second of gynecological cancer, showing younger trend and severely threatening the physical and mental health of women \[[@CR2]\]. At present, the treatment of endometrial cancer included surgery, radiotherapy, and chemotherapy, while patients with advanced EC may have distant metastasis, postoperative recurrence, and poor prognosis. Therefore, exploring potential biomarkers closely associated with the occurrence and development of EC are of great value for early diagnosis and targeted therapy of endometrial carcinoma.

Long noncoding RNAs (lncRNAs) are a group of non-coding RNAs with more than 200 bp in length with no or limited protein-coding function, which were first discovered in mice in 2002 and lack of specific and complete open reading frame \[[@CR3]\]. LncRNAs, as important regulators of transcription and translation, have been found not only involved in physiological and pathological processes, including chromatin remodeling, transcription, post-transcriptional translation, cell proliferation, differentiation and metabolic reprogramming \[[@CR4], [@CR5]\], but also playing a pivotal role in the occurrence and development of malignant tumors \[[@CR6]\]. Abnormal expression of lncRNAs can affect the development and progression of many kinds of malignant tumors, such as prostate cancer \[[@CR7]\], ovarian cancer \[[@CR8]\], breast cancer \[[@CR9]\] and gastric cancer \[[@CR10]\]. In recent years, a variety of lncRNAs have been identified to be essential for the initiation, progression and malignant behaviors of endometrial carcinoma \[[@CR11]\]. High expression of MALAT1 \[[@CR12]\], HOTAIR \[[@CR13]\] and NEAT1 \[[@CR14]\] were closely associated with the poor prognosis of EC and promoted the proliferation, metastasis and EMT of endometrial cancer cells. Other studies have shown that the expression of MEG3 \[[@CR15]\] and FER1L4 \[[@CR16]\] were decreased in EC, and high expression of MEG3 and FER1L4 inhibited the proliferation, migration and invasion of endometrial cancer cells. These studies suggest that lncRNAs play a crucial role in the prognosis and malignant biological behaviors of EC.

In this study, we investigated the differentially expressed lncRNAs in EC based on the Cancer Genome Atlas (TCGA) database and identified two lncRNA RP11-89K21.1 and RP11-357H14.17 and their correlation with the occurrence, development, prognostic value and functional regulatory network of EC. We also explored the upstream transcriptional regulatory factors, co-expression genes and binding proteins of lncRNAs and their relationship with immune infiltration. Furthermore, we explored their potential roles and molecular mechanisms in EC utilizing competing endogenous RNA (ceRNA) (lncRNA-miRNA-mRNA) hypothesis, which is extremely meaningful to provide a new strategy for early diagnosis and treatment of endometrial carcinoma.

Materials and methods {#Sec2}
=====================

Screening for differentially expressed lncRNAs by circlncRNAnet {#Sec3}
---------------------------------------------------------------

CirclncRNAnet (<http://120.126.1.61/circlnc/index.php>) \[[@CR17]\] is an online tool for exploring lncRNA and circRNA chip or sequencing expression data integrated with more than 20 tumor types in TCGA database, which included several analysis modules, such as heat map, box diagram, co-expression scatter map, circos map, gene functional enrichment analysis, RBP-RNA binding protein network and miRNA network. We explored the differentially expressed lncRNAs in EC based on Uterine Corpus Endometrial Carcinoma (UCEC) with circlncRNAnet, and constructed Circos map and heat map of LncRNAs co-expression genes, Pearson's correlation analysis was employed for exhibiting significant correlation between co-expressed genes and these lncRNAs (default: \|r\| \> 0.5). A total of 10,978 lncRNAs were identified in the cohort and we obtained 121 dysregulated lncRNAs (77 upregulated and 44 downregulated).The screening criteria were defined as follows: \|Log2 fold change \| \> 4 and *P* \< 0.01.

The prognosis of dysregulated lncRNAs analyzed with GEPIA and Kaplan--Meier plotter {#Sec4}
-----------------------------------------------------------------------------------

GEPIA (<http://gepia.cancer-pku.cn/>) \[[@CR18]\] is a newly web-based tool that contains sequencing expression data from 9736 tumor samples of 33 cancer types and 8587 normal samples. The database includes a variety of analysis modules such as differential gene expression analysis, survival and prognosis analysis, correlation analysis, as well as dimensionality reduction analysis. In this study, GEPIA database was employed to further analyze the expressionand prognostic value of differentially expressed lncRNAs in UCEC. The expression analysis of these genes performed by one-way ANOVA, and the filter criteria were as follows: \|Log2FC\| \> 1, *P* value \< 0.05, "median", Hazards Ratio (HR) and 95% confidence interval. The Kaplan--Meier (KM) Plotter (<http://kmplot.com>) \[[@CR19]\] is an effective tool for detecting the prognosis of patients with tumors. According to the expression of lncRNAs, patients with EC were divided into two groups: high and low expression group. The hazard ratio (HR) at a 95% confidence interval and log-rank *P*-values were also investigated online. The filter conditions were as follows: cancer: pan-cancer RNA-seq (Uterus corpus endometrial carcinoma); survival: overall survival (OS); follow-up threshold: 120 months.

The cellular localization of lncRNAs {#Sec5}
------------------------------------

UCSC (<https://genome-asia.ucsc.eduk/index.html>) \[[@CR20]\] provides a web-based interface that helps users browse gene information, view genome annotation assemblies and download gene sequences. LNCipedia (<https://lncipedia.org>) \[[@CR21]\] is a freely available annotated database of human lncRNAs transcriptional sequences and structures, which utilizes secondary structure information to establish a standard and unified classification and naming system. The tool offers insights into functions of over 1500 human lncRNAs, including evaluating coding ability, predicting open reading frame and secondary structure. LncLocator (<https://LncLocatorwww.csbio.sjtu.edu.cn/bioinf/lncLocator/>) \[[@CR22]\] is a free public platform to predict the subcellular localization of lncRNAs based on a stacked ensemble classifier. Only by utilizing lncRNA sequence information, the distribution proportion of lncRNA in 5 subcellular localizations, including cytoplasm, nucleus, ribosome, cytosol and exosome, can be quickly obtained. In this study, lncRNAs sequences information were detected by UCSC and LNCipedia databases, and the cellular localization of lncRNAs were then determined by LncLocator.

Prediction and expression of candidate miRNA with AnnoLnc and starBase database {#Sec6}
-------------------------------------------------------------------------------

AnnoLnc (<http://annolnc.cbi.pku.edu.cn>) \[[@CR23]\] is a web interface to systematically annotate newly identified human lncRNAs based on more than 700 data sources. The systematic annotation of lncRNAs cover a wide range of functions, including genome location, secondary structure, expression pattern, transcriptional regulation, miRNA interaction, protein interaction, genetic association and evolution. StarBase (<http://starbase.sysu.edu.cn/>) \[[@CR24]\] provides an widely-used open-source platform for exploring ncRNA interactions based on 10,882 RNA sequence and 10,546 miRNA sequence of 32 cancer types, the platform can be used to perform the survival and differential expression analysis of miRNAs and lncRNAs. We predicted lncRNAs-binding miRNAs with AnnoLnc and further explored the expression of miRNAs in UCEC by starBase.

Protein--protein interaction network and transcriptional regulatory network {#Sec7}
---------------------------------------------------------------------------

GeneMANIA (<http://www.genemania.org>) \[[@CR25]\] is a flexible and user-friendly platform that can predict gene function, analyze gene lists and sequence genes with function assays, which provides three main cases: single gene queries, multiple gene queries and network search. The online tool can be used to construct protein--protein interaction (PPI) network and protein-DNA interaction, investigate potential signal pathway, gene and protein expression and protein domains. We explored lncRNA-related proteins and transcriptional regulatory molecules with AnnoLnc, and visualized the functions and regulatory networks of these molecules using GeneMANIA.

Construction of lncRNA--miRNA--mRNA regulatory network {#Sec8}
------------------------------------------------------

miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/php/index.php>) \[[@CR26]\] is a popular web interface which mainly collects miRNA target genes verified by different validation experiments and provides supportive evidences with literatures or assays. The database can be queried through different categories, such as miRNA, gene, disease, pathway and so on. Cytoscape \[[@CR27]\] is a very powerful software for visualizing and analyzing network data, which allows users to construct many complex biological networks. Node and edge are the two core elements in the network diagram constructed by Cytoscape. miRNA target genes were explored by miRTarBase, and only those genes verified by at least one powerful experimental method were identified as miRNAs targets (reporter assay, Western blot or quantitative reverse transcription PCR). Cytoscape 3.7.1 was further employed to construct competing endogenous RNA (ceRNA) network (lncRNA-miRNA-mRNA).

Functional enrichment analysis with Metascape {#Sec9}
---------------------------------------------

Metascape (<http://metascape.org>) \[[@CR28]\] is a user-friendly and effective tool for comprehensively annotating and analyzing single or multiple genes lists, which integrates many authoritative database resources such as Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), UniProt and Drugbank. We can not only complete pathway enrichment and biological process annotation, but also construct protein--protein interaction (PPI) networks with Metascape. In this study, Metascape was used to analyze the GO and KEGG enrichment of differentially expressed genes related to lncRNAs. Restrictions: *P* \< 0.01, a minimum count of 3, enrichment factor \> 1.5 were considered to be statistically significant. The PPI enrichment analysis in Metascape was based on the following databases: BioGrid, InWeb_IM and OmniPath. In addition, Molecular Complex Detection (MCODE) algorithm is applied to mine molecules with deeper network regulation relationships.

Correlation between lncRNAs and immune infiltration analyzed with ImmLnc {#Sec10}
------------------------------------------------------------------------

ImmLnc (<http://bio-bigdata.hrbmu.edu.cn/ImmLnc>) \[[@CR29]\] is an online analysis website for investigating the immune-related function of lncRNAs across 33 cancer types with high-throughput methods, Users can investigated the lncRNA-pathways, lncRNA-immune cell type's correlation, and cancer-related lncRNAs. The ImmLnc serves as a valuable resource for exploring the lncRNA function and to further advance the identification of immunotherapy targets. In this study, we explored the correlation between lncRNAs and immune cell infiltration with ImmLnc.

Results {#Sec11}
=======

Identification of differentially expressed lncRNAs in Uterine Corpus Endometrial Carcinoma (UCEC) with circlncRNAnet and GEPIA {#Sec12}
------------------------------------------------------------------------------------------------------------------------------

To investigated the roles of lncRNAs in the tumorigenesis, development of UCEC, we firstly identified differentially expressed lncRNAs in the LncRNA-TCGA module of cirlncRNAnet. A total of 10,978 lncRNAs were detected in Uterine Corpus Endometrial Carcinoma (UCEC), of which 121 lncRNAs were dysregulated (77 up-regulated and 44 down-regulated) (\|Log2 fold change\| \> 4 and *P *\< 0.01) (Additional file [1](#MOESM1){ref-type="media"}: Table S1). We further verified the expression of 121 differentially expressed lncRNAs in UCEC using the GEPIA and found that only RP11-89K21.1 and RP11-357H14.17 were significantly overexpressed in UCEC (*P *\< 0.05) (Fig. [1](#Fig1){ref-type="fig"}a, b), consistent with the results from cirlncRNAnet. The expression of CTD-2314B22 0.1, CTD-2377D24.6, RP11-657O9.1 and LINC00668 were higher in UCEC than those in normal tissues, but the differences were not statistically significant (*P *\> 0.05) (Fig. [1](#Fig1){ref-type="fig"}c--f). The expression of AP000892.6, ACTA2-AS1 and RP11-867G23.10 was significantly decreased in UCEC compared with normal tissues (*P* \< 0.05) (Fig. [1](#Fig1){ref-type="fig"}h--i).Fig. 1Expression levels of dysregulated lncRNAs in patients with UCEC validated with GEPIA. **a**, **b** RP11-89K21.1 and RP11-357H14.17 were significantly upregulated validated with GEPIA (both *P *\< 0.05). **c--f** The expression levels of CTD-2314B22.1, CTD-2377D24.6, RP11-657O9.1 and LINC00668 in UCEC (all *P *\> 0.05). **g--i** AP000892.6, ACTA2-AS1, and RP11-867G23.10 were significantly downregulated in UCEC validated with GEPIA (all *P *\< 0.05). TPM:Transcripts per Million

Prognostic values of dysregulated lncRNAs including RP11-89K21.1 and RP11-357H14.17 in UCEC analyzed by GEPIA {#Sec13}
-------------------------------------------------------------------------------------------------------------

We further explored the prognostic values of the 121 differentially expressed lncRNAs in UCEC using GEPIA. The results showed that high expressions of RP11-89K21.1, RP11-357H14.17, CTD-2314B22.1, CTD-2377D24.6, RP11-657O9.1 and LINC00668 were significantly correlated with shortened overall survival (OS) in UCEC (*P *= 0.0088, *P *= 0.025, *P *= 0.026, *P *= 0.0013, *P *= 0.021, and *P *= 0.0086, respectively) (Fig. [2](#Fig2){ref-type="fig"}a--f, Table [1](#Tab1){ref-type="table"}). Additionally, the expressions of AP000892.6, ACTA2-AS1 and RP11-867G23.10 were decreased in UCEC, while high expressions of AP000892.6, ACTA2-AS1 and RP11-867G23.10 were significantly associated with poor prognosis (all *P *\< 0.05) (Fig. [2](#Fig2){ref-type="fig"}g--i). Kaplan--Meier plotter showed that high expressions of RP11-89K21.1 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1a), LINC00668 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1d) and ACTA2-AS1 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1e) were also correlated with OS in UCEC (Additional file [1](#MOESM1){ref-type="media"}: Table S1), RP11-357H14.17, CTD-2377D24.6 and AP000892.6 were not detected in Kaplan--Meier plotter. The above results suggest that high expression of RP11-89K21.1 and RP11-357H14.17 may play important roles in the occurrence, development and prognosis of UCEC.Fig. 2Prognostic values of dysregulated lncRNAs including RP11-89K21.1 and RP11-357H14.17 in UCEC analyzed by GEPIA. **a--i** Relationship between RP11-89K21.1 (**a**), RP11-357H14.17 (**b**), CTD-2314B22.1 (**c**), CTD-2377D24.6 (**d**), RP11-657O9.1 (**e**), LINC00668 (**f**), AP000892.6 (**g**), ACTA2-AS1 (**h**), RP11-867G23.10 (**i**) and overall survival (OS) of patients with UCECTable 1The expression levels and prognostic values of differentially expressed lncRNAs including RP11-89K21.1 and RP11-357H14.17 in UCECGeneEnsembl IDGenome locationLog2 fold change*P* adjOverall survivalRP11-89K21.1ENSG00000259439chr2:44921077-449391997.1136676063.31E − 320.0088RP11-357H14.17ENSG00000272763chr17:48635923-486470235.642192243.26E − 280.025CTD-2314B22.1ENSG00000258314chr14:19054341-190555515.4151176415.14E − 110.026CTD-2377D24.6ENSG00000244649chr17:48705203-487073465.3814935764.72E − 210.0013RP11-657O9.1ENSG00000240086chr3:135373795-1354398224.6295551761.49E − 090.021LINC00668ENSG00000265933chr18:6925478-69285724.0894251041.05E − 110.0086AP000892.6ENSG00000280143chr11:117204967-117210292− 4.082590091.28E − 360.013ACTA2-AS1ENSG00000180139chr10:88932390-88933838− 4.1643624722.49E − 360.036RP11-867G23.10ENSG00000254510chr11:66409194-66417137− 4.7375632541.01E − 290.0013

The cellular location and co-expressed genes of RP11-89K21.1 and RP11-357H14.17 {#Sec14}
-------------------------------------------------------------------------------

The cellular localization of lncRNAs played crucial roles in their functions and molecular mechanisms, we explored the subcellular localizations of RP11-89K21.1 and RP11-357H14.17 with lncLocator. The results showed that RP11-89K21.17 was mainly located in cytosol and cytoplasm (score: 0.56 and 0.28, respectively), RP11-357H14.17 was mainly located in cytosol and ribosome (score: 0.37 and 0.32, respectively) (Fig. [3](#Fig3){ref-type="fig"}a). Therefore, it was more likely that RP11-89K21.1 and RP11-357H14.17 exerted their biological functions and potential mechanisms through the ceRNA network. We further explored the co-expression gene of RP11-89K21.1 and RP11-357H14.17 and visualized by Circos map and heat map with circlncRNAnet. The circos maps showed that chromosome distribution of the top 50 co-expressed genes associated with RP11-89K21.1 and RP11-357H14.17, which were mainly localized in the autosomes. There was no particular enrichment in chromosome 2 (where RP11-89K21.1 locates) and 7 (where RP11-357H14.17 locates). The heat map indicated that AC012354.6, RP11-89K21.2, SIX3, SIX3-AS1, and Six3os1_1/2/4/5 were the co-expression gene of RP11-89K21.1, CTD-2377D24.6, HOXB-AS4, HOXB9 and MIR196A1 were the co-expression gene of RP11-357H14.17 (all *P *\< 0.05) (Fig. [3](#Fig3){ref-type="fig"}b, c, Additional files [2](#MOESM2){ref-type="media"}, [3](#MOESM3){ref-type="media"}).Fig. 3The cellular location and co-expression genes of RP11-89K21.1 and RP11-357H14.17 in UCEC. **a** Subcellular localizations of RP11-89K21.1 and RP11-357H14.17 in UCEC indicated by lncLocator. **b** Genome-wide distribution of the co-expressed genes correlated with the RP11-89K21.1 and RP11-357H14.17 in UCEC showed by Circos maps with circlncRNAnet (top 50). Red: genes with positive correlation; blue: genes with negative correlation; small dots: genes enrichment in human chromosome. **c** The genes co-expressed with RP11-89K21.1 and RP11-357H14.17 in UCEC showed by heat maps with circlncRNAnet (Pearson's correlation coefficient: \|r\| \> 0.5, *P*-value \< 0.05). Z-score: standard score

Transcriptional regulation and protein interaction of RP11-89K21.1 and RP11-357H14.17 {#Sec15}
-------------------------------------------------------------------------------------

Furthermore, we explored the transcriptional factors (TFs) and binding proteins of RP11-89K21.1 and RP11-357H14.17 by AnnoLnc. 31 TFs and 42 TFs were identified to be correlated with RP11-89K21.1 and RP11-357H14.17, respectively. 21 TFs of these two lncRNAs were commonly existed in the database (CEBPB, CHD1, c-Myc, CtBP2, CTCF, Egr-1, EZH2, GABP, Max, NRSF, p300, Pol2, Pol2-4H8, PU.1, Rad21, RBBP5, SUZ12, TCF7L2, YY1, Znf143, ZNF263) (Fig. [4](#Fig4){ref-type="fig"}a). We found that the expression of EZH2 in UCEC was significantly overexpressed, while the expression of TCF7L2 in UCEC was significantly decreased (both *P *\< 0.05). There was no significant difference in the expression levels of other TFs in UCEC (*P *\> 0.05) (Fig. [4](#Fig4){ref-type="fig"}b). We further investigated that EZH2 expression was positively correlated with both RP11-89K21.1 and RP11-357H14.17 using starBase (r = 0.118, *P *= 5.67e-03 and r = 0.103, *P *= 1.57e-02, respectively) (Fig. [4](#Fig4){ref-type="fig"}c). Based on the correlation coefficients were too small, we further explored the correlation between EZH2 and RP11-89K21.1, RP11-357H14.17 using GEPIA, the result showed that the expression of EZH2 was positively correlated with both RP11-89K21.1 (R = 0.3, *P *= 8.8e-07) and RP11-357H14.17 (R = 0.31, *P *= 3.7e-07) (Fig. [4](#Fig4){ref-type="fig"}d). What's more, the binding proteins of RP11-89K21.1 included CBWD7, GUSB, ABRA, MTUS2, VAMP4 (top 5) (Fig. [4](#Fig4){ref-type="fig"}e), and the binding proteins of RP11-357H14.17 included CLIC1, CNN2, TCTN1, TMEM240, ZNF836 (top 5) (Fig. [4](#Fig4){ref-type="fig"}f). The networks of the transcription factors (Fig. [4](#Fig4){ref-type="fig"}e) and binding proteins (Fig. [4](#Fig4){ref-type="fig"}f) were visualized through GeneMANIA (Additional files: [4](#MOESM4){ref-type="media"}, [5](#MOESM5){ref-type="media"}, [6](#MOESM6){ref-type="media"}, [7](#MOESM7){ref-type="media"}).Fig. 4Transcriptional regulation and protein interaction of RP11-89K21.1 and RP11-357H14.17. **a** The common transcriptional factors of RP11-89K21.1 and RP11-357H14.17 showed by Venny. **b** The expression levels of TCF7L2 and EZH2 by GEPIA. **c** The correlation between EZH2 and RP11-89K21.1, RP11-357H14.17 showed by scatter plot with Starbase. **d** The correlation between EZH2 and RP11-89K21.1, RP11-357H14.17 further displayed by scatter plot with GEPIA. **e** The network of transcriptional regulations of RP11-89K21.1 and RP11-357H14.17 with GeneMANIA. **f** The network of protein interactions of RP11-89K21.1 and RP11-357H14.17 with GeneMANIA, respectively. TPM: Transcripts per Million; LINC01833: the alternative gene name of RP11-89K21.1; AC103702.2: the alternative gene name of RP11-357H14.17

Construction of lncRNA--miRNA--mRNA network {#Sec16}
-------------------------------------------

The subcellular locations of lncRNAs were closely correlated with their potential functions and mechanisms in tumors. We found that both RP11-89K21.1 and RP11-357H14.17 were mainly located in cytosol, and it was possible that RP11-89K21.1 and RP11-357H14.17 achieved their biological functions through the ceRNA mechanism. Thus, the binding miRNAs of RP11-89K21.1 and RP11-357H14.17 were predicted by AnnoLnc. The expressions of potential miRNAs were further validated by starBase. The results showed that 22 miRNAs families and 10 miRNAs families were associated with RP11-89K21.1 and RP11-357H14.17, respectively. There were 5 miRNAs families overlapped in the lncRNAs binding miRNAs (Fig. [5](#Fig5){ref-type="fig"}a, Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2), of which the expression of miR-27b, miR-4770, miR-143, miR-204 in UCEC was significantly decreased (all *P *\< 0.05) (Fig. [5](#Fig5){ref-type="fig"}b--h). The expression of miR-125a-5p, miR-125b-5p, miR-139-5p, miR-670-3p, miR-24-1-5p, miR-503 in UCEC was also significantly decreased (all *P *\< 0.05) (Additional file [1](#MOESM1){ref-type="media"}: Figure S2, Table S2). For RP11-89K21.1, miR-27b, miR-4770, miR-143, miR-204, miR-125a-5p, miR-125b-5p, miR-139-5p and miR-670-3p were regarded as candidate miRNAs. For RP11-357H14.17, miR-27b, miR-4770, miR-143, miR-204, miR-24-1-5p and miR-503 were considered as candidate miRNAs. The targeted mRNAs of the candidate miRNAs were further predicted by miRTarBase. As shown in Fig. [6](#Fig6){ref-type="fig"}, lncRNA-miRNA-mRNA regulatory network was constructed by Cytoscape, there were 2 lncRNAs (RP11-89K21.1 and RP11-357H14.17), 11 miRNAs and 183 target genes included in the interaction network (Fig. [6](#Fig6){ref-type="fig"}).Fig. 5The expression of common binding miRNAs of RP11-89K21.1 and RP11-357H14.17 in UCEC with starBase. **a** The common binding miRNAs of RP11-89K21.1 and RP11-357H14.17 showed by Venny. **b--h** the expression levels of miR-27b (**b, c**), miR-4770 (**d**), miR-143 (**e**, **f**), miR-204 (**g, h**) were downregulated in UCEC compared with normal tissues (*P *\< 0.05)Table 2MiRNAs correlated with RP11-89K21.1 and RP11-357H14.17 predicted with AnnoLncLncRNAMiRNA familiesRP11-89K21.1miR-122/122a/1352miR-125a-5p/125b-5p/351/670/4319miR-125a-5p/125b-5p/351/670/4319miR-128/128abmiR-139-5pmiR-143/1721/4770miR-146ac/146b-5pmiR-146ac/146b-5pmiR-150/5127miR-192/215miR-194miR-1ab/206/613miR-200bc/429/548amiR-204/204b/211miR-21/590-5pmiR-216b/216b-5pmiR-218/218amiR-27abc/27a-3pmiR-34ac/34bc-5p/449abc/449c-5pmiR-455-5pmiR-490-3pmiR-7/7abRP11-357H14.17miR-204/204b/211miR-27abc/27a-3pmiR-192/215miR-138/138abmiR-34ac/34bc-5p/449abc/449c-5pmiR-34ac/34bc-5p/449abc/449c-5pmiR-143/1721/4770miR-24/24ab/24-3pmiR-503miR-138/138abFig. 6Construction of lncRNA-miRNA-mRNA regulatory network. The binding miRNAs of RP11-89K21.1 and RP11-357H14.17 were predicted by AnnoLnc, and the targets of these miRNAs were retrieved from the miRTarBase. The regulatory network of lncRNA-miRNA-mRNA was visualized using Cytoscape 3.7.1, including 2 lncRNAs (RP11-89K21.1 and RP11-357H14.17), 11 miRNAs and 183 target genes

Functional enrichment analysis of lncRNA-related targets {#Sec17}
--------------------------------------------------------

To explore the potential functions and mechanisms of RP11-89K21.1 and RP11-357H14.17 in the development of UCEC, GO and KEGG enrichment analysis of RP11-89K21.1 and RP11-357H14.17 targeted genes were analyzed by Metascape. GO showed that RP11-89K21.1 targeted genes primarily participated in transcription factor complex and perinuclear region of cytoplasm, also regulated proximal promoter sequence-specific DNA binding, phosphotransferase activity, kinase and growth factor binding (Fig. [7](#Fig7){ref-type="fig"}a--d, Additional file [1](#MOESM1){ref-type="media"}: Table S3--4). The biological processes of RP11-89K21.1 targeted genes mainly involved in blood vessel development, regulation of cell death and differentiation, tissue morphogenesis and response to growth factor (Fig. [7](#Fig7){ref-type="fig"}e--f and Table [3](#Tab3){ref-type="table"}). RP11-357H14.17 targeted genes were mainly located in perinuclear region of cytoplasm, participated in cyclin-dependent protein kinase holoenzyme complex, adherens junction and transcription factor complex, also regulated protein kinase activity.Fig. 7Significant enrichment analysis of GO and KEGG pathways of target genes correlated with RP11-89K21.1 in UCEC with Metascape. a-f Cellular component (**a, b**), molecular function (**c, d**) and biological process (**e, f**) enrichment analysis of RP11-89K21.1-related targets colored by *P*-value with bar graph and network (Top 20). **g, h** KEGG pathways enrichment analysis of RP11-89K21.1-related targets colored by *P*-value with bar graph and network (Top 20). **i** The PPI network formed by protein--protein interaction (PPI) network and the ten most significant MCODE components of RP11-89K21.1 target genes. *GO* Gene Ontology, *KEGG* Kyoto Encyclopedia of Genes and Genomes, *MCODE* Molecular Complex Detection. Above results were colored by *P*-value, where terms containing more genes tend to have a more significant *P*-valueTable 3Significantly enriched GO annotations (Biological Processes) of RP11-89K21.1 in endometrial carcinoma with Metascape (Top 20)GOCategoryDescriptionCount%Log10 (P)Log10 (q)GO:0001568GO Biological ProcessesBlood vessel development769.78− 41.51− 37.31GO:0097190GO Biological ProcessesApoptotic signaling pathway599.72− 31.73− 28.00GO:0010942GO Biological ProcessesPositive regulation of cell death638.53− 30.65− 27.15GO:0002521GO Biological ProcessesLeukocyte differentiation509.58− 26.49− 23.19GO:0048729GO Biological ProcessesTissue morphogenesis568.24− 26.38− 23.18GO:0007169GO Biological ProcessesTransmembrane receptor protein tyrosine kinase signaling pathway587.87− 26.32− 23.17GO:0019221GO Biological ProcessesCytokine-mediated signaling pathway607.54− 26.26− 23.14GO:0070482GO Biological ProcessesResponse to oxygen levels4411.17− 26.03− 22.98GO:0040008GO Biological ProcessesRegulation of growth558.02− 25.32− 22.42GO:0033674GO Biological ProcessesPositive regulation of kinase activity528.48− 25.06− 22.18GO:0030855GO Biological ProcessesEpithelial cell differentiation587.38− 24.89-22.03GO:0008285GO Biological ProcessesNegative regulation of cell proliferation577.37− 24.43− 21.59GO:1901652GO Biological ProcessesResponse to peptide488.99− 24.20− 21.38GO:0007507GO Biological ProcessesHeart development508.49− 24.09− 21.29GO:0080135GO Biological ProcessesRegulation of cellular response to stress567.32− 23.84− 21.07GO:0070997GO Biological ProcessesNeuron death4011.27− 23.81− 21.05GO:0048545GO Biological ProcessesResponse to steroid hormone4110.62− 23.41− 20.67GO:0030155GO Biological ProcessesRegulation of cell adhesion537.40− 22.76− 20.09GO:0007568GO Biological ProcessesAging3711.60− 22.47− 19.84GO:0045596GO Biological ProcessesNegative regulation of cell differentiation547.11− 22.38− 19.76

transcription factor and kinase binding (Fig. [8](#Fig8){ref-type="fig"}a--d, Additional file [1](#MOESM1){ref-type="media"}: Table S5, 6). RP11-89K21.1 targeted genes mainly involved in biological processes such as blood vessel development, regulation of transferase activity, apoptotic signaling pathway, regulation of cell death and cell differentiation, response to oxygen levels (Fig. [8](#Fig8){ref-type="fig"}e--f and Table [4](#Tab4){ref-type="table"}).Fig. 8Significant enrichment analysis of GO and KEGG pathways of target genes correlated with RP11-357H14.17 in UCEC with Metascape. **a--f** Cellular component (**a, b**), molecular function (**c, d**) and biological process (**e, f**) enrichment analysis of RP11-357H14.17-ralated targets colored by *P*-value with bar graph and network (Top 20). **g, h** KEGG pathways enrichment analysis of RP11-357H14.17-related targets colored by *P*-value with bar graph and network (Top 20). **i** The PPI network formed by protein--protein interaction (PPI) network and the ten most significant MCODE components of RP11-357H14.17 target genes. GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; MCODE: Molecular Complex Detection. Above results were colored by *P*-value, where terms containing more genes tend to have a more significant *P*-valueTable 4Significantly enriched GO annotations (Biological Processes) of RP11-357H14.17 in endometrial carcinoma with Metascape (Top 20)GOCategoryDescriptionCount%Log10 (P)Log10 (q)GO:0001568GO Biological ProcessesBlood vessel development709.01− 39.16− 34.96GO:0051347GO Biological ProcessesPositive regulation of transferase activity608.67− 32.38− 28.66GO:0097190GO Biological ProcessesApoptotic signaling pathway569.23− 31.55− 27.95GO:0010942GO Biological ProcessesPositive regulation of cell death597.98− 29.87− 26.52GO:0070482GO Biological ProcessesResponse to oxygen levels4411.17− 28.12− 24.97GO:0045596GO Biological ProcessesNegative regulation of cell differentiation577.51− 27.45− 24.42GO:0070848GO Biological ProcessesResponse to growth factor567.61− 27.24− 24.24GO:0048732GO Biological ProcessesGland development4510.18− 27.04− 24.07GO:0080135GO Biological ProcessesRegulation of cellular response to stress567.32− 26.39− 23.49GO:0040008GO Biological ProcessesRegulation of growth517.43− 24.28− 21.47GO:0048729GO Biological ProcessesTissue morphogenesis507.35− 23.57− 20.81GO:0009611GO Biological ProcessesResponse to wounding507.24− 23.26− 20.51GO:0072593GO Biological ProcessesReactive oxygen species metabolic process3411.89− 22.61− 19.92GO:0019221GO Biological ProcessesCytokine-mediated signaling pathway526.53− 22.18− 19.53GO:0048545GO Biological ProcessesResponse to steroid hormone379.59− 21.30− 18.68GO:1901652GO Biological ProcessesResponse to peptide427.87− 20.86− 18.26GO:0010035GO Biological ProcessesResponse to inorganic substance437.62− 20.83− 18.25GO:0070997GO Biological ProcessesNeuron death359.86− 20.55− 18.00GO:0097191GO Biological ProcessesExtrinsic apoptotic signaling pathway2912.95− 20.37− 17.82GO:0002521GO Biological ProcessesLeukocyte differentiation417.85− 20.34− 17.80

KEGG enrichment analysis showed that RP11-89K21.1 targeted genes were significantly enriched in pathways in cancer, endocrine resistance and microRNAs in cancer, regulated apelin signaling pathway, Th17 cell differentiation and hippo signaling pathway (Fig. [7](#Fig7){ref-type="fig"}g, h, Table [5](#Tab5){ref-type="table"}). RP11-357H14.17 targeted genes were significantly enriched in pathways in cancer, microRNAs in cancer, PI3K-AKT signaling pathway, AGE-RAGE signaling pathway in diabetic complications, cell cycle and cytokine-mediated signaling pathway (Fig. [8](#Fig8){ref-type="fig"}g, h, Table [6](#Tab6){ref-type="table"}). These signaling pathways played key roles in the occurrence and development of a variety of tumors, including endometrial carcinoma. Moreover, in order to better understand the relationship between RP11-89K21.1, RP11-357H14.17 and UCEC, we performed protein--protein interaction (PPI) enrichment analysis using Metascape (Figs. [7](#Fig7){ref-type="fig"}i, [8](#Fig8){ref-type="fig"}i). The most important 10 and 8 MCODE components in PPI network, pathway and enrichment process analysis were applied to each MCODE component independently.Table 5Significantly enriched KEGG pathway of RP11-89K21.1 in endometrial carcinoma with Metascape (Top 20)GOCategoryDescriptionCount%Log10 (P)Log10 (q)hsa05200KEGG PathwayPathways in cancer6115.44− 44.75− 42.06hsa01522KEGG PathwayEndocrine resistance3233.33− 34.89− 32.68hsa05206KEGG PathwayMicroRNAs in cancer4515.05− 32.32− 30.23hsa05219KEGG PathwayBladder cancer1843.90− 22.42− 20.98hsa04371KEGG PathwayApelin signaling pathway2215.94− 16.49− 15.42hsa05202KEGG PathwayTranscriptional misregulation in cancer2111.67− 12.98− 12.02hsa04659KEGG PathwayTh17 cell differentiation1614.95− 11.70− 10.80hsa04670KEGG PathwayLeukocyte transendothelial migration1614.04− 11.27− 10.39hsa04390KEGG PathwayHippo signaling pathway1811.69− 11.22− 10.36hsa04520KEGG PathwayAdherens junction1318.06− 10.69− 9.84hsa04060KEGG PathwayCytokine-cytokine receptor interaction197.04− 8.02− 7.26hsa04137KEGG PathwayMitophagy-animal913.85− 6.54− 5.82hsa04115KEGG Pathwayp53 signaling pathway913.04− 6.31− 5.60hsa04022KEGG PathwaycGMP-PKG signaling pathway137.98− 6.28− 5.58hsa04350KEGG PathwayTGF-beta signaling pathway910.71− 5.58− 4.90hsa04330KEGG PathwayNotch signaling pathway714.58− 5.36− 4.69hsa05144KEGG PathwayMalaria714.29− 5.30− 4.64hsa04621KEGG PathwayNOD-like receptor signaling pathway127.06− 5.29− 4.64hsa05132KEGG PathwaySalmonella infection89.30− 4.56− 3.94hsa04913KEGG PathwayOvarian steroidogenesis510.00− 3.19− 2.61Table 6Significantly enriched KEGG pathway of RP11-357H14.17 in endometrial carcinoma with Metascape (Top 20)GOCategoryDescriptionCount%Log10 (P)Log10 (q)hsa05200KEGG PathwayPathways in cancer57/39514.43− 42.91− 40.22hsa05206KEGG PathwayMicroRNAs in cancer47/29915.72− 36.99− 34.60hsa04151KEGG PathwayPI3K-Akt signaling pathway46/34213.45− 33.06− 30.84hsa04933KEGG PathwayAGE-RAGE signaling pathway in diabetic complications29/9929.29− 31.22− 29.22hsa04110KEGG PathwayCell cycle25/12420.16− 22.51− 21.02hsa05202KEGG PathwayTranscriptional misregulation in cancer23/18012.78− 16.11− 14.80hsa05230KEGG PathwayCentral carbon metabolism in cancer16/6524.62− 16.07− 14.78hsa04668KEGG PathwayTNF signaling pathway18/10816.67− 14.80− 13.55hsa04060KEGG PathwayCytokine-cytokine receptor interaction25/2709.26− 14.14− 12.92hsa04066KEGG PathwayHIF-1 signaling pathway17/10116.83− 14.08− 12.88hsa05162KEGG PathwayMeasles18/13413.43− 13.10− 11.98hsa05144KEGG PathwayMalaria12/4924.49− 12.16− 11.06hsa05216KEGG PathwayThyroid cancer10/2934.48− 11.90− 10.86hsa04520KEGG PathwayAdherens junction13/7218.06− 11.31− 10.30hsa04659KEGG PathwayTh17 cell differentiation15/10714.02− 11.29− 10.29hsa04390KEGG PathwayHippo signaling pathway17/15411.04− 11.00− 10.02hsa04064KEGG PathwayNF-kappa B signaling pathway12/9512.63− 8.61− 7.76hsa04350KEGG PathwayTGF-beta signaling pathway11/8413.10− 8.11− 7.27hsa04670KEGG PathwayLeukocyte transendothelial migration12/11410.53− 7.70− 6.86hsa04360KEGG PathwayAxon guidance13/1757.43− 6.49− 5.73

Correlation between the expression of RP11-89K21.1, RP11-357H14.17 and immune infiltration with ImmucLnc {#Sec18}
--------------------------------------------------------------------------------------------------------

In order to investigate the relationship between RP11-89K21.1, RP11-357H14.17 and immune infiltration, ImmucLnc database was employed to detect RP11-89K21.1, RP11-357H14.17 correlated immune cell types (CD8_T cell, Macrophage, Dendritic, BMSCs and CD4_T cell, and Neutrophil). We found that the expression of RP11-89K21.1 was negatively correlated with CD8_T cell (Rs Value = − 0.159, *P *= 0) and Macrophage (Rs Value = − 0.11, *P *= 0.01), and positively correlated with CD4_T cell (Rs Value = 0.106, *P *= 0.013) and Neutrophil (Rs Value = 0.138, *P *= 0.001) (Table [7](#Tab7){ref-type="table"}). The expression of RP11-357H14.17 was negatively correlated with CD8_T cell (Rs Value = − 0.114, *P *= 0.008) and positively correlated with CD4_T cell (Rs Value = 0.102, *P *= 0.017) (Table [8](#Tab8){ref-type="table"}).Table 7Correlation of RP11-89K21.1 with immune infiltration analyzed by ImmucLncCancerLncRNA IDLncRNA symbolImmune cell*P* valueRs value^b^UCECENSG00000259439LINC01833^a^CD8_T cell0− 0.159UCECENSG00000259439LINC01833Macrophage0.01− 0.11UCECENSG00000259439LINC01833Dendritic0.981− 0.001UCECENSG00000259439LINC01833B_cell0.4040.036UCECENSG00000259439LINC01833CD4_T cell0.0130.106UCECENSG00000259439LINC01833Neutrophil0.0010.138^a^ LINC01833 the alternative gene name of RP11-89K21.1, ^b^ The correlation coefficientTable 8Correlation of RP11-357H14.17 with immune infiltration analyzed by ImmucLncCancerLncRNA IDLncRNA symbolImmune cell*P* valueRs value^a^UCECENSG00000272763RP11-357H14.17CD8_T cell0.008− 0.114UCECENSG00000272763RP11-357H14.17Dendritic0.072− 0.077UCECENSG00000272763RP11-357H14.17Macrophage0.101− 0.07UCECENSG00000272763RP11-357H14.17B_cell0.279− 0.046UCECENSG00000272763RP11-357H14.17Neutrophil0.307− 0.044UCECENSG00000272763RP11-357H14.17CD4_T cell0.0170.102^a^ The correlation coefficient

Discussion {#Sec19}
==========

A series of biological processes are involved in the occurrence and progression of EC, such as abnormal expression of genes and transcription factors, dysregulation of cellular signal transduction pathway and imbalance of cell microenvironment homeostasis. Pathological changes and molecular characteristics determine the level of risk and prognosis of patients with EC. In recent years, 1ncRNAs have been identified to exert various malignant biological behaviors in EC including differentiation, proliferation, invasion and metastasis \[[@CR30]\]. Therefore, it is valuable and helpful to explore the potential functions and molecular mechanisms of lncRNAs in EC, which contribute to prognostic prediction and therapeutic target of endometrial carcinoma.

In this study, 121 differentially expressed lncRNAs in UCEC were identified by circlncRNAnet, including 77 upregulated and 44 downregulated lncRNAs. We further confirmed for the first time that only high expressions of RP11-89K21.1 and RP11-357H14.17 were significantly associated with shortened OS and poor prognosis of patients with UCEC, which suggested that RP11-89K21.1 and RP11-357H14.17 played oncogene roles in the occurrence, progression of endometrial carcinoma. It was reported that the expression of lncRNAs were regulated by transcription factors \[[@CR31]\]. We found that EZH2 was the common transcriptional regulator of RP11-89K21.1 and RP11-357H14.17 in endometrial carcinoma with AnnoLnc, Moreover, EZH2 was positively correlated with the expression of RP11-89K21.1 and RP11-357H14.17. Some studies have showed that lncRNA DLEU2 interacted with EZH2 to promote the proliferation, migration and invasion of hepatocellular carcinoma, thus accelerating the malignant progression of hepatocellular carcinoma \[[@CR32]\]. In gastric cancer, lncRNA UCA1 enhanced the translation of cyclin D1 via recruiting EZH2 and further precipitated the proliferation and cell cycle progression of gastric cancer \[[@CR33]\]. In lung cancer, the expression of lncRNA-SVUGP2 could be suppressed by EZH2 and further promoted the occurrence and development of lung cancer via Wnt/β-catenin pathway \[[@CR34]\]. These studies suggest that there exists potential regulatory mechanism between EZH2 and RP11-89K21.1, RP11-357H14.17 involved in the occurrence and development of endometrial carcinoma, and the specific mechanism remains to be further explored and verified.

Studies have shown that lncRNAs are located in different subcellular structures, including cytoplasm, nucleus, ribosome, cytosol and exosome. Functions and regulatory mechanisms of lncRNAs are closely associated with subcellular localization. We detected that RP11-89K21.1 and RP11-357H14.17 were mainly located in cytosol. Growing evidence suggested that, in the cytoplasm and cytosol, lncRNAs not only regulated the stability and translation of mRNA, but also had an impact on the post-transcriptional modification of proteins and cell signal transduction. Based on the ceRNA hypothesis, lncRNA can competitively bind to miRNAs acting as sponge of miRNAs, detaining or adsorbing miRNAs, thus relieving the inhibition of miRNAs on downstream target genes \[[@CR35], [@CR36]\]. Some studies have shown that exosomal lncRNA ARSR could competitively bind to miR-34 and miR-449 to regulate the expression of AXL, c-MET, and then promoted the drug resistance of renal cell carcinoma \[[@CR37]\]. In prostate cancer, lncRNA TTTY15 acted as a ceRNA and negatively regulated miR-let-7 to promote expression of the target genes (CDK6, FN1) \[[@CR38]\]. In recent years, mounting studies have shown that lncRNA, acting as ceRNA, regulated the expression of downstream oncogenes and tumor suppressor genes in endometrial carcinoma through a miRNA regulatory mechanism. In endometrial carcinoma, lncRNA HOTAIR facilitated the expression of NPM1 by negatively regulating miR-646, and thereby promoting the proliferation, migration and invasion of EC cells \[[@CR39]\]. Maziveyi et al. reported that lncRNA TUSC7 promoted the expression of SOCS4 (SOCS5) through acing as sponge of miR-616, thus inhibiting the proliferation, migration and invasion of endometrial carcinoma \[[@CR40]\]. We further explored the potential role of ceRNA network mechanism regulated by RP11-89K21.1 and RP11-357H14.17 in the progression of EC. The binding miRNAs of RP11-89K21.1 and RP11-357H14.17 were retrieved from miRTarBase and 4 overlapped miRNAs (miR-27b, miR-4770, miR-143, miR-204) were downregulated in UCEC, and other RP11-89K21.1 binding miRNA (miR-125a-5p, miR-125b-5p, miR-139-5p, miR-670-3p) and RP11-357H14.17 binding miRNA (miR-24-1-5p, miR-503) were also decreased in UCEC. miRNAs were involved in a variety of malignant biological behaviors and mechanisms such as proliferation, invasion and migration of tumors. The expression of miR-27b-3, miR-204-5p was decreased in EC, and high expression of miR-27b-3 and miR-204-5p could significantly inhibit the proliferation, migration and invasion of EC cells \[[@CR41], [@CR42]\]. The expression of miR-143 and miR-503 were also downregulated in EC, and high expression of miR-503 inhibited the proliferation and cell cycle of EC cells through negatively regulating CCND1 \[[@CR43], [@CR44]\]. These findings indicated that RP11-89K21.1 and RP11-357H14.17 may play oncogene roles in endometrial carcinoma by regulating candidate miRNAs and their targeted genes. Therefore, we have successfully constructed a new lncRNA-miRNA-mRNA ceRNA regulatory network associated with the prognosis of patients with EC, and further experiments are required to verify molecular mechanisms in the regulatory network.

Many studies have shown that lncRNAs affects the initiation and development of tumors by regulating a variety of molecular mechanisms and signaling pathways. Researchers observed lncRNA LSINCT5 promoted proliferation, invasion and metastasis of EC cells by regulating HMGA2/Wnt/β-catenin signaling pathway \[[@CR45]\]. LncRNA OGFRP1 promoted the malignant progression of endometrial carcinoma by regulating the miR124-3p/SIRT1 axis and activating the PI3K/AKT/GSK-3β pathway \[[@CR46]\]. In order to better clarify the biological function, molecular mechanism and regulatory network of RP11-89K21.1 and RP11-357H14.17-related targeting genes in EC, we carried out GO and KEGG enrichment analysis with Metascape. It was found that RP11-89K21.1 and RP11-357H14.17-related targeting genes were mainly involved in vasculature development, tissue morphogenesis, cell growth and differentiation, regulation of protein kinase activity and cellular response to stress. KEGG enrichment analysis showed that RP11-89K21.1 and RP11-357H14.17-related targeting genes were significantly enriched in microRNAs in cancer, cytokine-mediated signaling pathway, transmembrane receptor protein tyrosine kinase signaling pathway, apoptotic signaling pathway. The above signaling pathways were closely associated the progression and biological behaviors of EC \[[@CR47]\]. Therefore, we speculated that RP11-89K21.1 and RP11-357H14.17 can affect the occurrence, development and biological behavior of EC by regulating the above tumor-related pathways, which provided more evidences for further exploring the molecular mechanisms of RP11-89K21.1 and RP11-357H14.17 in endometrial carcinoma.

Accumulating studies have demonstrated that a large number of immune cells and cytokines can be observed in EC, which can enhance the endogenous anti-tumor immune response and affect prognostic value and immunotherapy of EC. Immunotherapy plays a well-established role in the treatment of EC. Our results showed that the expression of RP11-89K21.1 was negatively correlated with CD8_T cell, Macrophage and positively correlated with CD4_T cell, Neutrophil. The expression of RP11-357H14.17 was negatively correlated with CD8_Tcell and positively correlated with CD4_Tcell. Studies have shown that CD8_T cell and Macrophage could participate in the malignant progression of EC and serve as a potential therapeutic target for EC \[[@CR48]\]. CD4_T cell could promote the capacity of initiating CD4_T cell rapidly by mediating immune response, and kill tumor cells directly or indirectly by stimulating and recruiting CD8_T cell cells or other immune cells \[[@CR49]\]. The number of CD4_T cells in peripheral blood of patients with EC was significantly increased \[[@CR50]\]. Neutrophil was the main type of immune cells in tumors, which can eliminate pathogens and prevent host from being infected by microorganisms, playing a key role in chemotherapy resistance and anti-angiogenesis therapy of tumors \[[@CR51]\]. Some studies have displayed that neutrophils were closely correlated with survival and prognosis of patients with EC \[[@CR52]\]. The results showed that the above immune cells were of great value in the occurrence, development and prognosis of EC. However, it's not sufficient to conclude that RP11-89K21.1 and RP11-357H14.17 play critical role in regulating the infiltration of immune cells in tumor microenvironment because of the small correlation coefficients (Rs value), and further experiments are required to verify the function of RP11-89K21.1 and RP11-357H14.17 in immune infiltration.

Conclusion {#Sec20}
==========

In summary, with a series of integrated databases, we demonstrated for the first time that high expressions of RP11-89K21.1 and RP11-357H14.17 were closely associated with the poor prognosis of patients with EC. We further identified transcriptional regulatory factors, co-expressed genes, interacting proteins of RP11-89K21.1 and RP11-357H14.17. Regulatory networks of biological function, signaling pathways may contribute to illuminate the potential function and mechanism of RP11-89K21.1 and RP11-357H14.17 in EC. Moreover, we speculated that the ceRNA network associated with RP11-89K21.1 and RP11-357H14.17 provided novel and valuable insights into the molecular mechanisms underlying the initiation and progression of EC. Therefore, RP11-89K21.1 and RP11-357H14.17 can potentially be identified as tumor biomarkers for early diagnosis, prognosis evaluation and therapeutic targets of EC. Although existing research may not be optimal, we think it should be adequate to make a conclusion that RP11-89K21.1 and RP11-357H14.17 contributed to poor prognosis in EC. The functional experiments of RP11-89K21.1 and RP11-357H14.17 will be further conducted in the follow-up study.
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